ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
83,245
0,58%
Bitcoin
64 105,42
0,33%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Pasithea Therapeutics Corporation (KTTA)

  7. Pasithea Therapeutics Corporation (KTTA) Actualités

KTTA Pasithea Therapeutics Corporation

6,92
0,00 (0,00%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Pasithea Therapeutics Corporation KTTA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 6,92 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
7,17 7,17 7,17 6,92 6,92
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
29/4/202413:59GLOBEPasithea Therapeutics Announces PAS-004 Abstract Accepted..
24/4/202413:59GLOBEPasithea Therapeutics Announces the First Cohort has..
02/3/202403:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202403:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202403:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202403:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202413:59GLOBEPasithea Therapeutics Announces Opening of Enrollment in the..
18/1/202422:30EDGAR2Form 8-K - Current report
08/1/202413:59GLOBEPasithea Therapeutics Announces Invention of Crystalline..
02/1/202422:47EDGAR2Form 8-K - Current report
02/1/202414:35GLOBEPasithea Therapeutics Announces FDA Acceptance of IND..
28/12/202323:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/12/202323:00GLOBEPasithea Therapeutics Announces Adjournment of Reconvened..
28/12/202317:30EDGAR2Form 8-K - Current report
19/12/202323:26EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
19/12/202323:21EDGAR2Form 8-K - Current report
19/12/202323:19GLOBEPasithea Therapeutics Announces Results from 2023 Annual..
11/12/202314:01GLOBEPasithea Therapeutics Announces Positive In Vivo Preclinical..
29/11/202323:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/11/202322:27GLOBEPasithea Therapeutics Announces Adjournment of 2023 Annual..
29/11/202313:59GLOBEPasithea Therapeutics Announces Outcome of Pre-IND Meeting..
13/11/202322:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:59GLOBEPasithea Therapeutics Selects PAS-003 Lead Development..
26/10/202323:01EDGAR2Form ARS - Annual Report to Security Holders
26/10/202323:00EDGAR2Form DEF 14A - Other definitive proxy statements
16/10/202323:18EDGAR2Form PRE 14A - Other preliminary proxy statements
13/10/202323:00EDGAR2Form 8-K - Current report
14/9/202315:15EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
14/9/202315:11EDGAR2Form 8-K - Current report
14/9/202314:30GLOBEPasithea Therapeutics Corp. Announces Final Results of..
07/9/202322:14GLOBEPasithea Therapeutics to Participate in H.C. Wainwright 25th..
24/8/202323:00EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
21/8/202323:22EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
14/8/202315:02EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
11/8/202323:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202315:08EDGAR2Form SC TO-I - Tender offer statement by Issuer
01/8/202313:59GLOBEPasithea Therapeutics publishes study in Proceedings of the..
20/7/202315:03EDGAR2Form SC TO-C - Written communication relating to an issuer..
20/7/202314:56EDGAR2Form 8-K - Current report
20/7/202314:43GLOBEPasithea Therapeutics Announces Intention to Commence a..
20/7/202314:40GLOBEPasithea Therapeutics Special Committee Rejects Unsolicited..
20/7/202314:31EDGAR2Form 8-K - Current report
03/7/202323:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
30/6/202315:28GLOBEPasithea Therapeutics Confirms Previous Creation of..
29/6/202320:50GLOBELucy Scientific Discovery Reiterates Its Proposal to Acquire..
29/6/202314:29GLOBEPasithea Therapeutics Announces Completion of GMP..
06/6/202322:30GLOBEPasithea Therapeutics Confirms Receipt of Unsolicited..
05/6/202315:00GLOBELucy Scientific Discovery Announces Proposal to Acquire..
01/6/202313:57GLOBEPasithea Therapeutics Abstract Accepted for Poster..

Dernières Valeurs Consultées

NASDAQ
KTTA
Pasithea Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés